New drug combo aims to control tough cancers in kids and adults
NCT ID NCT05210413
First seen Jan 18, 2026 · Last updated Jun 14, 2026 · Updated 23 times
Summary
This study tests a combination of two drugs (spartalizumab and low-dose pazopanib) in 80 children and adults whose solid tumors have not responded to standard treatments. The goal is to see if the combo can shrink or stabilize the cancer for at least 6 months. The pediatric part finds the safest dose, while the adult part measures how well the treatment controls the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY OR RECURRENT SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHM Hôpital des Enfants La Timone - Hématologie Oncologie Pédiatrique
Marseille, 13385, France
-
CHU d'Angers - Unité d'Hématologie et d'Oncologie pédiatrique
Angers, France
-
CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique
Bordeaux, 33076, France
-
Centre Léon Bérard - Oncologie Médicale
Lyon, 69373, France
-
Centre Oscar Lambret - Oncologie pédiatrie
Lille, 59020, France
-
Curie Institute
Paris, France
-
Gustave Roussy - Oncologie pédiatrique
Villejuif, 94805, France
-
Institut Bergonié - Oncologie Médicale
Bordeaux, 33076, France
-
Institut Curie - Centre D'Oncologie SIREDO
Paris, 75005, France
-
Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP) - Oncologie pédiatrique
Lyon, 69373, France
-
Nantes University Hospital
Nantes, France
-
Oscar Lambret Center
Lille, France
-
Strasbourg University Hospital
Strasbourg, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.